BeiGene, a company founded in 2010 by John V. Oyler and Xiaodong Wang, is focused on improving treatment outcomes and medical access for cancer patients worldwide. With the recent opening of its Dubai office, the company’s global workforce has now reached 11,000 employees, signaling a new phase of regional expansion. Of these employees, 3,000 are dedicated to medical affairs and clinical development, with 1,100 solely focused on cancer research.
According to Al-Kapany, cancer is the second leading cause of death globally. He has witnessed individuals diagnosed with cancer who couldn’t afford the necessary medication, as well as those who could afford it but chose not to undergo treatment in order to save money for their families. BeiGene’s mission is to create impactful and innovative medications that can benefit all cancer patients worldwide, offering them improved lives or even the possibility of a cure.
BeiGene’s first commercially available product in the region is zanubrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi) marketed under the name BRUNKINSA. This BTKi has shown promising results in the treatment of hematological malignancies and has already been approved in all six GCC countries and Egypt.
Al-Kapany ensures that zanubrutinib will be affordable for all eligible patients, regardless of any financial obstacles they may face. The company is committed to providing a fair and equitable opportunity for every patient to start and continue their treatment.
I have over 10 years of experience in the field of cryptocurrency and blockchain technology. I have attended numerous conferences and events around the world, and my work has been featured in major publications such as CoinDesk, Bitcoin Magazine, and Yahoo Finance.